There are currently 1874 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
NCT04752826
Recruiting
The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
NCT05262023
Recruiting
This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period. Part A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Frontotemporal Dementia
Register for Updates
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
NCT06162728
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 114, Philadelphia, Pennsylvania
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania +3 locations
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
NCT05274048
Recruiting
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation design in patients with metastatic or unresectable gastro-esophageal cancer that are HER2-overexpressing (IHC 3+ or IHC2+/ISH+) and any other gastrointestinal cancer with HER2 expression with IHC3+. Patients must have progressed or been intolerant of at least one prior line... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
Register for Updates
A Clinical Study of the TSX Dental Implant System (Xpresso)
NCT06571812
Recruiting
A prospective, observational, multicenter study where 62 patients needing implants in the maxilla or mandible will be enrolled. The patients will be restored with a final prosthesis no later than 4 months following implant placement surgery. The patients will come back for follow-up evaluations yearly for 2 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Tooth Loss
Register for Updates
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
NCT05496036
Recruiting
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Medicine, Philadelphia, Pennsylvania
Conditions: Merkel Cell Carcinoma
Register for Updates
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT05964504
Recruiting
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response assessment tool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Abramson Cancer Center, Philadelphia, Pennsylvania
Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Register for Updates
Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal
NCT05995535
Recruiting
A placebo-controlled trial in which male and female outpatients with an opioid use disorder who express interest in extended-release injectable naltrexone (XR-NTX) are randomized 1:1 to lofexidine/pregabalin or lofexidine/pregabalin placebo for withdrawal management and offered XR-NTX if after completing withdrawal.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania
Conditions: Opiate Withdrawal Syndrome, Opioid Use
Register for Updates
Flu Infection at UPHS
NCT06807840
Recruiting
Cellular and humoral immune responses in individuals with active influenza infection will be assessed. Each year, up to 50 participants will be enrolled. The investigators hypothesize that influenza infection will elicit mostly memory immune responses rather than de novo immune responses to infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Penn Presbyterian Medical Center, Philadelphia, Pennsylvania
Conditions: Influenza Human
Register for Updates
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
NCT06557785
Recruiting
This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses are: 1. the CH505M5 N197D mRNA-gp160 will expand CH235-like B cell precursors, 2. the CH505 TF mRNA-gp160 will boost CH235-like bnAb B cell precursors to acquire more functional m... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/28/2025
Locations: Penn Prevention (Site ID: 30310), Philadelphia, Pennsylvania
Conditions: HIV Infections
Register for Updates